Recently, reporters visited Traditional Chinese Medicine companies and Chinese medicinal herb planting bases in Shijiazhuang City and discovered that the inheritance of essence, adherence to authenticity, and innovation in research and production have made “Chinese Medicine” that is more suitable for the genetic heritage and physical characteristics of the Chinese people a unanimous choice. These vivid and practical examples demonstrate the city’s determination and strong drive to strengthen the inheritance, innovation, and industrialization of traditional Chinese medicine, accelerate its modernization, and build a bio-pharmaceutical industry cluster worth hundreds of billions.

Recently, in the liquid chromatography laboratory of Yiling Pharmaceutical Research Institute, staff members were conducting ultraviolet detection experiments. (Image provided by Yiling Pharmaceutical)

Bold innovation based on inheritance, striving for excellence in traditional Chinese medicine

On July 5, in the electrophysiology laboratory of Yiling Pharmaceutical, Wang Hongtao, the Vice Dean of Yiling Medical Research Institute, led his colleagues in conducting evaluation experiments on new anti-aging drugs using a set of extracorporeal membrane electrode marking system.

“The research on the basic theories of traditional Chinese medicine, especially the theory of collaterals, cannot do without the support of modern science and technology.” Wang Hongtao said that this anti-aging drug development platform alone has more than 200 sets of advanced research and development equipment, including a complete cardiovascular monitoring system such as single-cell contraction monitoring and ion channel monitoring, with a total value exceeding 50 million yuan.

By using high-tech and modern equipment, Yiling Pharmaceutical has boldly innovated based on inheritance, becoming the driving force behind its rapid development.

As early as the early 1990s, Yiling Pharmaceutical began in-depth research on the theory of collaterals and systematically constructed the theory of collaterals, establishing the “collateral disease theory and treatment” system. Under the guidance of the theory of collaterals, a number of world-leading high-tech new drug research and development platforms, including the National Key Laboratory of Collateral Disease Theory Innovation and Transformation, were established in collaboration with internationally renowned scientific research institutions in the UK, the Netherlands, and other countries.

How can more “Chinese Medicine” be developed and produced that are suitable for the genetic heritage and physical characteristics of the Chinese people under the guidance of new theories?

Yiling Pharmaceutical regards evidence-based medicine research as an important part of its innovative technology system for new drug development and has conducted more than 50 evidence-based medicine studies. The project “Construction of TCM Pulse Vascular Theory and Its Guided Microvascular Lesion Prevention and Treatment” that encompasses multiple evidence-based research results won the first prize of the National Science and Technology Progress Award. The research project “Study on the Intervention of the TCM Pulse Vascular Theory and Defense Theory System in Cardiovascular Event Chains,” which is part of the National Key R&D Program, followed international standards to complete five evidence-based studies on the intervention of collateral drugs in metabolic syndrome abnormal glucose tolerance, vulnerable plaques in coronary arteries, acute myocardial infarction, atrial fibrillation recurrence after radiofrequency ablation, and chronic heart failure, breaking through the bottleneck of single disease prevention and treatment and achieving a major breakthrough in the systematic intervention of cardiovascular event chains.

The combination of innovative traditional Chinese medicine theories and modern scientific and technological advancements has enabled Yiling Pharmaceutical to establish a unique advantage in the development of patented new drugs, as well as driving the development of compound Chinese medicines, component Chinese medicines, and monomer Chinese medicines through multiple channels. Currently, Yiling Pharmaceutical has established an integrated model of academic innovation and transformation in traditional Chinese medicine, combining theory, clinical practice, new drug development, experiments, and evidence-based medicine. They have developed more than ten patented Chinese medicine varieties, covering six major disease areas with high incidence rates, including cardiovascular, respiratory, endocrine, nervous, tumor, and urological diseases, forming a cluster of patented drugs at different stages of development.

Wang Hongtao stated that they will deepen the research on the basic theories of traditional Chinese medicine, utilize high-tech and modern equipment, carry out interdisciplinary collaborative research, further improve the independent intellectual property rights of new drug development systems, and develop and produce more “Chinese Medicine” that is suitable for the genetic heritage and physical characteristics of the Chinese people.

Recently, in Fangshan Village, Nanxing Township, Jingxing County, local residents are working in the planting base of Qiaozhi Chinese medicinal herbs. (Image provided by the Publicity Department of Jingxing County Committee)

The post Innovation, only to excel in “Chinese Medicine” appeared first on Publicist Paper.